Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

X4 Pharmaceuticals (XFOR) Leases (2019 - 2025)

X4 Pharmaceuticals filings provide 7 years of Leases readings, the most recent being $1.4 million for Q4 2025.

  • On a quarterly basis, Leases fell 65.34% to $1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 million, a 65.34% decrease, with the full-year FY2025 number at $1.4 million, down 65.34% from a year prior.
  • Leases hit $1.4 million in Q4 2025 for X4 Pharmaceuticals, down from $1.8 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $9.8 million in Q1 2021 to a low of $1.4 million in Q4 2025.
  • Median Leases over the past 5 years was $6.3 million (2023), compared with a mean of $6.1 million.
  • Biggest five-year swings in Leases: skyrocketed 473.6% in 2021 and later plummeted 65.34% in 2025.
  • X4 Pharmaceuticals' Leases stood at $8.7 million in 2021, then dropped by 17.0% to $7.2 million in 2022, then fell by 21.84% to $5.6 million in 2023, then fell by 28.05% to $4.1 million in 2024, then plummeted by 65.34% to $1.4 million in 2025.
  • The last three reported values for Leases were $1.4 million (Q4 2025), $1.8 million (Q3 2025), and $2.6 million (Q2 2025) per Business Quant data.